Switching between GLP‑1 medicines isn’t as simple as matching “milligrams to milligrams.” Even when two pens contain the same molecule (like semaglutide), the approved indication, dose range, titration pace, and the way your body tolerates the medicine can differ. A safe switch is clinician‑led: it’s planned around your current dose, side‑effects, medical history, and goals, then monitored during the first few weeks after the change.

Table of Contents

When switching makes sense

People usually ask about switching because of one of these scenarios:

You’re on Ozempic (or another GLP‑1) and your clinician is moving you to a weight‑management plan.
You’re having persistent side effects and need a different titration approach.
Supply/availability issues mean your current medication isn’t reliably in stock.
You’re changing treatment goals (for example, focusing more on weight loss rather than glucose control).

Before you switch: the clinician safety checklist

A prescriber will usually review the same fundamentals as a new start, plus a few “switch‑specific” checks:

Your indication and eligibility (BMI criteria and/or weight‑related conditions where relevant).
Contraindications and red flags (for example, prior severe allergic reaction to a GLP‑1 medicine).
Current dose, the day you last injected, and how you’ve tolerated dose increases so far.
Other medicines-especially diabetes medicines that can increase hypoglycaemia risk when combined.
Recent symptoms that could suggest a serious side effect (for example, severe abdominal pain).

The core principle: avoid dose-conversion mistakes

Clinicians avoid “direct dose conversion charts” as a one-size-fits-all solution. Instead, they choose a starting Wegovy dose that fits your recent tolerance and then re‑titrate safely. This is because side effects often relate to how quickly the dose increases, not just the final maintenance dose.

Timing: when to take your first Wegovy dose after your last GLP‑1

Most weekly GLP‑1 medicines are switched by aligning with the next scheduled injection day. In practical terms, that usually means:

You take your last dose of your current weekly GLP‑1 as scheduled.
You wait until your next planned weekly injection day (usually ~7 days later).
You start Wegovy on that day-unless your clinician advises a longer gap due to side effects or other factors.

If you’ve had significant nausea, vomiting, dehydration, or poor oral intake, your clinician may delay the first Wegovy dose or step you down to a lower starting dose to reduce the risk of symptoms flaring again.

If timing gets confusing, keep these two rules handy:

Don’t take two weekly GLP‑1 injections too close together (stacking doses increases side‑effect risk).
If you miss or delay a dose, follow a clear timing rule rather than guessing.

See: Missed dose of Wegovy (timing rules)

How the starting Wegovy dose is chosen (practical approach)

Your clinician will typically choose the starting Wegovy dose based on two things: (1) what you were taking before, and (2) how well you tolerated it.

If you are switching from Ozempic (semaglutide)

Ozempic and Wegovy both contain semaglutide, but they are licensed and titrated differently. Many clinicians still start conservatively-especially if you had gastrointestinal side effects on Ozempic or if your dose increases were recently difficult.

Common clinician-led patterns include:

If you were stable and tolerating semaglutide well, your clinician may start at a mid‑titration Wegovy dose (rather than restarting at the very beginning).
If you recently had side effects or you had interruptions in treatment, your clinician may restart lower (often 0.25 mg or 0.5 mg) and build back up.
If you were already at the top end of your previous semaglutide regimen and tolerating it well, your clinician may transition you into the later stages of Wegovy titration with careful monitoring.

If you are switching from other GLP‑1 medicines

If you’re coming from a different GLP‑1 (e.g., liraglutide daily injections or other weekly GLP‑1s), a prescriber will usually treat the switch like a new start and titrate gradually. That’s because dose units and pharmacology differ across brands, and tolerance doesn’t always “transfer” perfectly.

Titration after the switch: follow the Wegovy schedule unless told otherwise

After your starting dose, the default approach is to follow Wegovy’s step‑up schedule and only increase when you’re tolerating the current dose. If symptoms are strong at any step, clinicians may hold the dose for longer, step down, or pause increases.

Reference: Wegovy dosage schedule (0.25 → 2.4 mg)

What to expect in the first 2-4 weeks after switching

The first month is about stabilising. Even if you were previously on a GLP‑1, you may notice changes because:

The titration pace may differ from what you previously used.
Your appetite and satiety signals can shift with the new dosing stage.
Gastrointestinal effects can reappear temporarily during a dose change (especially nausea, constipation, or diarrhoea).

Most mild to moderate side effects settle with time and supportive strategies (hydration, smaller meals, slower eating, avoiding very fatty meals during the early weeks). If symptoms are persistent or worsening, it’s a signal to contact your prescriber rather than pushing through.

See symptom guidance: Wegovy side effects (common vs serious)

Monitoring and dose safety (especially if you have diabetes)

If you have type 2 diabetes and are switching treatments, monitoring is more important-not because Wegovy is “dangerous,” but because your overall regimen may need adjustment. Risk of low blood sugar is most relevant when Wegovy is combined with insulin or sulfonylureas.

Read: Does Wegovy cause low blood sugar?

Clinicians may ask you to:

Track glucose readings more often during the first 1-2 weeks after switching (if you have diabetes).
Record symptoms (nausea, vomiting, dizziness, fatigue) and hydration status.
Confirm your injection day and set reminders to avoid accidental early dosing.

How to inject safely during a switch

Switching is a good time to re-check injection technique. Incorrect technique can worsen site reactions or lead to uncertainty about whether a full dose was delivered.

Helpful guides: How to use the Wegovy pen and Best injection sites + rotation plan

Red flags: when you should seek urgent medical advice

Contact urgent medical services (or your clinician urgently) if you develop symptoms that could indicate a serious adverse event. Examples include severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, signs of dehydration, or any severe allergic reaction.

Clear urgent-action criteria: When to stop Wegovy & seek medical help

If you’re switching because of supply issues

If shortages or stock issues are driving the switch, avoid buying medication from unofficial sources. Counterfeit or mishandled cold-chain medicines are a real risk with injectables.

FAQ

Can I switch from Ozempic to Wegovy immediately?

Usually, clinicians plan the first Wegovy dose for your next scheduled weekly injection day. The exact plan depends on your current dose and how you’ve tolerated it.

Do I need to restart at 0.25 mg when switching?

Not always. Some people can start higher if they’ve been stable and well‑tolerant on another GLP‑1. If you’ve had side effects, interruptions, or dose uncertainty, restarting lower is often safer.

Is there an “equivalent dose” chart I can follow myself?

Self‑converting doses is risky. Dose units across products aren’t directly interchangeable, and the titration pace matters. A prescriber should set the plan.

Will switching bring side effects back?

It can. Any dose change can trigger a temporary return of nausea or bowel changes. Most settle with time, but worsening symptoms should be reviewed.

What if I accidentally take two weekly injections too close together?

Contact your clinician for personalised advice. Monitor for nausea, vomiting, dehydration, and low blood sugar risk if you use diabetes medicines.

Can I switch if I’m on other diabetes medicines?

Yes, but your prescriber may adjust insulin or sulfonylurea doses and may recommend closer glucose monitoring during the transition.